WINTON GROUP Ltd Sells 31,800 Shares of Encompass Health Corporation $EHC

WINTON GROUP Ltd cut its holdings in Encompass Health Corporation (NYSE:EHC) by 93.8% in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 2,100 shares of the company’s stock after selling 31,800 shares during the quarter. WINTON GROUP Ltd’s holdings in Encompass Health were worth $212,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also made changes to their positions in the stock. BlackRock Inc. bought a new position in shares of Encompass Health during the 2nd quarter worth approximately $1,059,762,000. Geode Capital Management LLC grew its stake in Encompass Health by 7.6% during the 4th quarter. Geode Capital Management LLC now owns 1,946,134 shares of the company’s stock valued at $206,605,000 after purchasing an additional 137,892 shares during the last quarter. Dimensional Fund Advisors LP increased its holdings in shares of Encompass Health by 3.1% in the first quarter. Dimensional Fund Advisors LP now owns 1,674,784 shares of the company’s stock valued at $162,013,000 after purchasing an additional 50,647 shares during the period. Norges Bank purchased a new position in shares of Encompass Health in the fourth quarter worth about $133,221,000. Finally, Arrowstreet Capital Limited Partnership raised its stake in shares of Encompass Health by 9.0% in the fourth quarter. Arrowstreet Capital Limited Partnership now owns 1,163,834 shares of the company’s stock worth $123,529,000 after purchasing an additional 96,445 shares during the last quarter. 97.25% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of equities research analysts recently commented on EHC shares. Wall Street Zen lowered Encompass Health from a “buy” rating to a “hold” rating in a research report on Saturday, September 5th. Weiss Ratings upgraded shares of Encompass Health from a “hold (c+)” rating to a “buy (b-)” rating in a research note on Wednesday, August 12th. Truist Financial upped their price objective on shares of Encompass Health from $140.00 to $150.00 and gave the company a “buy” rating in a report on Friday, August 7th. UBS Group increased their price objective on shares of Encompass Health from $150.00 to $155.00 and gave the stock a “buy” rating in a research note on Friday, August 7th. Finally, Barclays raised their target price on shares of Encompass Health from $140.00 to $144.00 and gave the stock an “overweight” rating in a report on Thursday, August 6th. One research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has issued a Hold rating to the company. According to data from MarketBeat.com, Encompass Health has an average rating of “Buy” and an average target price of $148.20.

Insiders Place Their Bets

In other news, EVP John Darby sold 8,906 shares of the firm’s stock in a transaction dated Monday, August 10th. The stock was sold at an average price of $125.95, for a total transaction of $1,121,710.70. Following the sale, the executive vice president directly owned 75,041 shares in the company, valued at $9,451,413.95. This trade represents a 10.61% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Mark J. Tarr sold 173,148 shares of the company’s stock in a transaction dated Monday, August 10th. The stock was sold at an average price of $125.47, for a total value of $21,724,879.56. Following the completion of the transaction, the chief executive officer directly owned 267,814 shares of the company’s stock, valued at $33,602,622.58. The trade was a 39.27% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 186,912 shares of company stock valued at $23,434,845 in the last ninety days. 1.80% of the stock is owned by corporate insiders.

Encompass Health Trading Down 1.1%

Shares of NYSE:EHC opened at $121.84 on Friday. The company has a current ratio of 1.19, a quick ratio of 1.19 and a debt-to-equity ratio of 0.76. Encompass Health Corporation has a 12-month low of $92.77 and a 12-month high of $127.99. The business has a 50 day moving average of $118.44 and a two-hundred day moving average of $108.60. The company has a market capitalization of $12.02 billion, a PE ratio of 19.84, a PEG ratio of 2.49 and a beta of 0.75.

Encompass Health (NYSE:EHC) last issued its quarterly earnings data on Wednesday, August 5th. The company reported $1.55 EPS for the quarter, topping analysts’ consensus estimates of $1.48 by $0.07. The business had revenue of $1.60 billion for the quarter, compared to analysts’ expectations of $1.57 billion. Encompass Health had a net margin of 10.01% and a return on equity of 18.08%. The business’s revenue was up 9.6% on a year-over-year basis. During the same quarter last year, the company earned $1.40 EPS. Encompass Health has set its FY 2026 guidance at 6.020-6.250 EPS. As a group, analysts forecast that Encompass Health Corporation will post 6.08 EPS for the current year.

Encompass Health Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Thursday, October 15th. Investors of record on Thursday, October 1st will be given a dividend of $0.21 per share. This is a boost from Encompass Health’s previous quarterly dividend of $0.19. This represents a $0.84 annualized dividend and a yield of 0.7%. The ex-dividend date is Thursday, October 1st. Encompass Health’s dividend payout ratio (DPR) is 12.38%.

Encompass Health Profile

Encompass Health Corporation (NYSE:EHC) is a provider of post-acute healthcare services in the United States. The company operates inpatient rehabilitation hospitals that care for patients recovering from illness, injury, surgery or other medical conditions requiring intensive rehabilitation.

Its rehabilitation programs commonly serve patients recovering from strokes, brain and spinal cord injuries, neurological disorders, cardiac and pulmonary conditions, hip fractures, amputations and other orthopedic conditions.